We speculate that glioma subtypes that have longer periods of disease latency after treatment, such as low-grade gliomas or MGMT-methylated glioblastoma, may have a higher burden of senescent cells than gliomas that recur more rapidly, such as MGMT-unmethylated glioblastoma. Here, MGMT is linked to central nervous system cancer.